Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
The hospital stay following percutaneous kidney biopsy (PKB) is convention-based, lacking risk-based criteria. We aimed to develop a practical scoring tool to optimize hospitalization.
We conducted a retrospective cohort study using a nationwide administrative claims inpatient database (2016–2021). We included adults undergoing native PKB, excluding transplant recipients and extreme BMI (<15 or ≥50). The primary outcome was major bleeding (transfusion or surgical/endovascular intervention within 6 days after biopsy). Logistic regression assessed the association of clinical diagnosis and hemostatic agents with bleeding risk. The ridge regression model was built using training data from four Japanese regions, and the regularization parameter was selected through 10-fold cross-validation. Variables with large coefficients were used to construct the Kidney biopsy Blood transfusion Index for Triage (K-BIT). External validation was performed using data from two additional regions.
Among 85,450 patients (median age 58; hospital day 6), 1.99% had major bleeding. Compared to chronic glomerulonephritis, bleeding risk was highest in rapidly progressive glomerulonephritis or ANCA-associated vasculitis (adjusted OR 8.95; 95% CI, 7.41–10.82) and acute kidney injury (OR 14.52; 95% CI, 11.65–18.10). Hemostatic agents were used in 53.6% of patients. Carbazochrome sulfonate (OR, 0.69; 95% CI, 0.58–0.85) and its combination with tranexamic acid (OR, 0.79; 95% CI, 0.69–0.90) were associated with reduced bleeding risk, particularly in the subgroup population with proteinuria or nephrotic syndrome. In the test dataset, K-BIT (range –1 to 10) incorporates age, diagnosis tier, BMI, and medication (Figure). In the external validation cohort, scores ≤2 (57.1% of cohort; low and very low risk category) had a bleeding risk of 0.50%, compared with 1.91% overall. If all patients were discharged same-day, the bleeding risk would be 1.91%. Restricting early discharge to scores ≤2 achieves an event rate of 0.5% and reduces hospitalization by 342 days per 100 patients, supporting substantial resource savings while maintaining patient safety (Figure).
Pre-biopsy clinical diagnosis and age are strong predictors of bleeding risk. Hemostatic agents, especially carbazochrome-based regimens, may reduce the bleeding risk. K-BIT score offers safe short-stay PKB and substantial resource savings.
